Form 4: Trevi Therapeutics CEO Jennifer Good Executes Stock Option and Sells Shares

Trevi Therapeutics CEO Jennifer Good exercised stock options and sold shares on May 20, 2024, according to a Form 4 filing with the SEC.

Summary

• On May 20, 2024, Jennifer Good, the President & CEO and a director of Trevi Therapeutics, Inc., exercised a stock option to acquire 25,037 shares of common stock at a price of $2.19 per share.
• Simultaneously, Ms. Good sold 25,037 shares of common stock at a weighted average price of $2.8588, with individual sales prices ranging from $2.82 to $2.955.
• Following these transactions, Ms. Good directly owns 213,313 shares of Trevi Therapeutics common stock.
• Ms. Good also holds options to purchase 33,189 shares of common stock.

Sentiment

Score: 5

Explanation: The document reflects a neutral sentiment as it simply reports a transaction. It doesn't inherently indicate positive or negative outlook for the company.

Industry Context

Executive stock transactions are common and are often scrutinized by investors for insights into management's perspective on the company's future prospects. This transaction represents a routine execution of vested stock options and a subsequent sale of shares.

Comparison to Industry Standards

• Executive compensation packages often include stock options as incentives.
• The vesting schedule described is typical for stock options granted to executives.
• Monitoring insider transactions is a standard practice in financial analysis to gauge sentiment.

Stakeholder Impact

• Shareholders may interpret the sale as a lack of confidence, although option exercises and sales are common.
• The transaction has a minimal direct impact on employees, customers, suppliers, or creditors.

Key Dates